The Chinese pharmacopoeia and standards of the ministry of Traditional Chinese medicine contain Arisaematis rhizoma for external use analysis of medication law
Konferenz: BIBE 2019 - The Third International Conference on Biological Information and Biomedical Engineering
20.06.2019 - 22.06.2019 in Hangzhou, China
Tagungsband: BIBE 2019
Seiten: 3Sprache: EnglischTyp: PDFPersönliche VDE-Mitglieder erhalten auf diesen Artikel 10% Rabatt
Gao, Ting; Bai, Ming; Miao, Mingsan (Henan University of Chinese Medicine, Zhengzhou, China)
Objective: To analyze the law of external use of Chinese patent medicine containing Arisaematis rhizoma. Methods: According to the 2015 edition of the Chinese Pharmacopoeia and the Ministry of Standards, the data on the external treatment of Arisaematis rhizoma Chinese Medicine is used as the data source. Excel 2013, Clementine12.0 and SPSS Statistics19.0 statistical software are used as tools to statistically process the Chinese medicines included in the standard. Analysis of association rules. Results: Among all formulations included in the inclusion criteria, the top six herbs with the highest cumulative frequency are Arisaematis rhizoma (39, 100%), Angelicae dahuricae radix (27, 69.23%), Borneolum (25, 64.10%), Aconiti kusnezoffii radix (23, 58.97%), Camphor (20,51.28%) and Aconiti radix (20, 51.28%). Through the association rule analysis of the Chinese patent medicine containing Arisaematis rhizoma for external use, it is found that there are 11 kinds of common drugs and 9 kinds of common clinical diseases. Conclusion: Through the analysis of the external treatment of Chinese patent medicine containing Arisaematis rhizoma, the law and compatibility characteristics of Arisaematis rhizoma in the treatment of different diseases are reflected. Mathematical statistics is an important tool for the analysis of the law of Chinese medicine, providing more accurate basis for guiding clinical medication.